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Background: HIV infection among children, particularly those under 24 months of age, is often rapidly progressive;
as a result guidelines recommend earlier access to combination antiretroviral therapy (cART) for HIV infected
children. Losses to follow-up (LTFU) and death in the interval between diagnosis and initiation of ART profoundly
limit this strategy. This study explores correlates of LTFU and death prior to ART initiation among children.
Methods: The study is based on 337 HIV-infected children enrolled into care at an urban centre in The Gambia,
including those alive and in care when antiretroviral therapy became available and those who enrolled later.
Children were followed until they started ART, died, transferred to another facility, or were LTFU. Cox proportional
hazards regression models were used to determine the hazard of death or LTFU according to the baseline
characteristics of the children.
Results: Overall, 223 children were assessed as eligible for ART based on their clinical and/or immunological status
among whom 73 (32.7%) started treatment, 15 (6.7%) requested transfer to another health facility, 105 (47.1%) and
30 (13.5%) were lost to follow-up and died respectively without starting ART. The median survival following eligibility
for children who died without starting treatment was 2.8 months (IQR: 0.9 - 5.8) with over half (60%) of all deaths
occurring at home. ART-eligible children less than 2 years of age and those in WHO stage 3 or 4 were significantly
more likely to be LTFU when compared with their respective comparison groups. The overall pre-treatment mortality
rate was 25.7 per 100 child-years of follow-up (95% CI 19.9 - 36.8) and the loss to programme rate was 115.7 per 100
child-years of follow-up (95% CI 98.8 - 137). In the multivariable Cox proportional hazard model, significant
independent predictors of loss to programme were being less than 2 years of age and WHO stage 3 or 4. The
Adjusted Hazard Ratio (AHR) for loss to programme was 2.06 (95% CI 1.12 – 3.83) for being aged less than 2 years
relative to being 5 years of age or older and 1.92 (95% CI 1.05 - 3.53) for being in WHO stage 3 or 4 relative to WHO
stage 1 or 2.
Conclusions: Earlier enrolment into HIV care is key to achieving better outcomes for HIV infected children in
developing countries. Developing strategies to ensure early diagnosis, elimination of obstacles to prompt initiation
of therapy and instituting measures to reduce losses to follow-up, will improve the overall outcomes of HIV-infected
children.
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Combination antiretroviral therapy (cART) has signifi-
cantly improved the prognosis for HIV-infected children
in resource-limited settings [1-4]. Eligibility for ART
among children in resource-limited settings is based on
either clinical and/or immunological criteria to start
treatment at World Health Organization (WHO) clinical
stage 3 or 4 disease, or at a CD4 T-cell count/percent
below the age-appropriate immunological threshold [5].
However, because of the more rapid disease progression
and significantly higher risk of mortality in the first two
years of life among HIV-infected children in sub-Saharan
Africa [6,7], WHO now recommends that all infants and
children aged <24 months with confirmed HIV-infection
start ART as soon as possible irrespective of clinical stage
or immunological threshold [5,7,8]. Unfortunately, the
majority of HIV-infected children in sub-Saharan Africa
are diagnosed late with advanced clinical disease and im-
munosuppression, and are usually 5 years of age or older
at initiation of therapy [2,4]. This is due to, among other
reasons, the fact that health systems in resource limited
settings still face considerable challenges in their efforts
to scale-up access to early paediatric HIV diagnosis and
treatment, particularly among children aged < 18 months
in whom a definitive diagnosis requires sophisticated
laboratory techniques. Another challenge that treatment
programmes face is ensuring that all children who test
HIV-positive are successfully linked to and retained in a
Paediatric HIV/AIDS care programme such that they can
initiate ART as soon as they are eligible [4,9]. Retention
of patients in pre-ART care is of paramount importance
in ensuring the success of ART programmes. Loss to care
has been defined as “discontinuation of active engage-
ment in pre-ART care for any reason, including death”
[10]. Loss to follow-up (LTFU) from HIV care pro-
grammes in particular represents missed opportunities
for the timely initiation of life-saving treatment. A sys-
tematic review of adult ART programmes in sub-Saharan
Africa reported that retention is as low as 60% after
2 years [11], which is consistent with our observation of
one-third of ART-eligible adults who died or were lost to
follow-up prior to initiation of treatment [12]. However,
there is a paucity of data on mortality and loss to follow-
up experiences of ART-eligible HIV-infected children
who fail to initiate treatment because this information is
not routinely assessed as part of program evaluations
[13-15].
In 2008, the prevalence of HIV-1 and HIV-2 in The
Gambia was estimated to be 1.6% and 0.4%, respectively
[16]. The prevalence of paediatric HIV/AIDS is amongst
the lowest in sub-Saharan Africa with less than 1000 chil-
dren below the age of 15 years known to be living with
HIV/AIDS [17]. Approximately one-third of these are
receiving life-saving ART though the proportion thatare eligible but are yet to initiate ART is unknown.
This study aims to investigate, and determine factors
associated with, pre-ART loss to follow-up and mor-
tality among ART-eligible HIV-infected children at the
Paediatric HIV clinic of the Medical Research Council
(MRC) Unit in Fajara, The Gambia – West Africa.
Results
Enrolment, follow-up and ART eligibility
A total of 411 HIV infected children attended the MRC
paediatric HIV clinic at least once between June 1993
and January 2010; of these, 74 were excluded from the
analysis because they had either died or were LTFU prior
to June 2004 when pre-ART sensitization and screening
began (Figure 1).
Among the 337 children in care between June 2004
and January 2010 and included in the analysis were
318 (94%) HIV-1 infected, 16 (5%) HIV-2 and 3 (1%)
HIV-1/HIV-2 dually infected children. Their median age
at diagnosis of HIV infection was 23 months (IQR: 12 –
71 months). Of these children, 126 (37%) were aged less
than 18 months, 119 (35.3%) aged between 18 – 59 months
and 92 (27.3%) 5 years or older at the time of diagnosis.
HIV-2 infected children were older at the time of HIV
diagnosis (median 65.6 months; IQR: 26 - 98) than HIV-1
(23.3 months; IQR: 12 – 62) and HIV-1/HIV-2 dually
infected children (10.2 months; IQR: 7.6 - 21.8) but this
was not statistically significant. 164 (49%) children were
female. Overall, 114 (34%) children did not meet ART
initiation criteria over this period while 223 (66%) chil-
dren were found to be eligible for treatment (Figure 1).
Characteristics of ART-eligible patients
The majority of children in the cohort were enrolled after
January 2006 with eligibility based on the 4-stage 2006
revision of the WHO paediatric treatment guidelines
(Table 1). 177 (80%) of the children were eligible to start
cART at presentation or within 6 months of their being
diagnosed with HIV infection; 60% of the children were
2 years of age or older at eligibility. Information on par-
ental vital status was available for 173 of the 223 children,
of which half were orphaned: 70 (41%) had lost one par-
ent and 16 (9%) had lost both parents. Only 99 (44%)
children had documentation of their parents HIV status -
76 had at least one HIV-positive parent, 17 had both par-
ents HIV-positive and 6 had both parents HIV-negative.
Gender, HIV type, CD4% and the vital status of the par-
ents were not significantly associated with the outcomes
of survival or retention but there were significant differ-
ences by age and WHO clinical status (Table 2); children
less than 2 years of age and those in WHO stage 3 or
4 at ART eligibility were significantly more likely to be
LTFU when compared with their respective comparison
groups.
Children aged < 15 years who attended the paediatric HIV clinic at least once between June 1993 and January 2010
(n=441)
Excluded before June 2004 [when pre-ART assessment began] (n = 74)
Lost to follow-up (n = 39)



















































Figure 1 Flow chart of the cohort of HIV-infected children < 15 years of age enrolled in the Paediatric HIV programme, MRC Unit, The
Gambia, 1993–2010.
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Among the 73 children who commenced cART; the
median time from eligibility to ART initiation and median
age at initiation were 5.1 months (IQR: 2.8 – 11.2) and
4.9 years (IQR: 2.6 – 9.9) respectively.
Thirty (13.3%) ART-eligible children died without
staring treatment giving a pre-treatment mortality rate of
25.7 per 100 child-years of follow-up (95% CI 19.9 –
36.8). The median survival following ART eligibility for
children who died without starting treatment was
2.8 months (IQR: 0.9 – 5.8) with over half (60%) of all
deaths occurring at home (Table 3).
One hundred and five (47%) treatment-eligible children
who remained in the cohort for a median of 4.2 months
(IQR: 3.4 – 5.3) were eventually LTFU before starting
treatment. Nineteen (18%) of these children were last seen
on the date that that they were diagnosed HIV-positive
and/or assessed to be eligible for ART and of these, 14
were less than 2 years of age. WHO clinical stage at eligi-
bility was documented in 75 of those lost to follow-up and
25 (33%) and 34 (45.3%) had a stage 3 and stage 4 condi-
tion respectively. Twenty-two (21%) of the children
LTFU had one or both parents in HIV care whilst 35
(33%) were either single or double orphans.A total of 135 ART-eligible children were lost to the
programme before ART initiation giving an incidence
rate for the composite endpoint of death or LTFU of
115.7 per 100 child-years of follow-up (95% CI 98.8 –
137). In both univariate and multivariable analyses of risk
factors for death, no significant risk factors were identi-
fied (Table 4); however being less than 2 years of age
at eligibility, having advanced clinical HIV disease
(i.e. WHO stage 3 or 4) and having been assessed as eli-
gible for ART between January 2006 and January 2010
were all significantly associated with loss to programme.
Figure 2 shows the cumulative incidence of loss to
programme overall, by age category, eligibility period and
WHO clinical stage at ART eligibility. The graphs show
significant unadjusted associations between age category
(log rank test, p = 0.0001), eligibility period (log rank test,
p = 0.0062), WHO clinical stage (log rank test, p = 0.0001)
and loss to programme risk from the time of being
assessed as ART-eligible. The unadjusted Hazard Ratio
for loss to programme was 2.41 (95% CI 1.61 – 3.61) for
children less than 2 years of age at the time of eligibility
compared with children 5 years of age or older; 2.43
(95% CI 1.51 – 3.90) for being in WHO stage 3 or 4 rela-
tive to WHO stage 1 or 2 and 1.86 (95% CI 1.18 – 2.93)
Table 1 Clinical and socio-demographic characteristics of
223 ART-eligible HIV-infected children enrolled in the






Eligibility period a : (n= 223)
June 2004 – December 2005 42 (18.8%)
January 2006 – January 2010 181 (81.2%)
Age at eligibility: (n=223)
Median in years (IQR) 2.9 (1.4 – 7.4)
< 2 years 89 (40%)
2 – 4 years 49 (22%)





WHO clinical stage at eligibility: (n=178)
1 or 2 63 (35.4%)
3 or 4 115 (64.6%)
CD4% at eligibility: (n=196)
Median (IQR) 11 (7 – 14)
<15% 151 (77.0%)
≥15% 45 (23.0%)
Haemoglobin at eligibility (n=192)
Median (IQR) 9.3 (7.9 – 10.3)
Haemoglobin < 8 g/dl 50 (26%)
Vital status of parents: (n=173)
One parent died 70 (40.5%)
Both died 16 (9.2%)
Both alive 87 (50.3%)
a Defined by age according to the WHO treatment guidelines in effect at the
time of eligibility.
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2006 and January 2010 compared to the period between
June 2004 and December 2005 (Table 4). In the multi-
variable Cox proportional hazard model, significant in-
dependent predictors of loss to programme were being
less than 2 years of age and WHO stage 3 or 4. Being
less than 2 years of age is the strongest independent pre-
dictor of loss to programme among ART-eligible
patients - the Adjusted Hazard Ratio (AHR) for loss to
programme was 2.06 (95% CI 1.12 – 3.83) for being aged
less than 2 years relative to being 5 years of age or older
and 1.92 (95% CI 1.05 – 3.53) for being in WHO stage 3
or 4 relative to WHO stage 1 or 2. The Proportional
hazards assumption was met for all Cox proportional
hazard models.Outcomes among HIV-infected children ineligible for ART
at enrollment
The 114 children who did not meet ART initiation cri-
teria over the study period were followed up for a median
of 1.7 months (IQR: 0.2 – 16.9) from enrolment. Twenty-
three (20.2%) children were transferred to another clinic,
88 (77.2%) were LTFU and 3 (2.6%) died; all deaths
occurred within three months of enrolment. All these
children had been given follow-up appointments no later
than 3 months after their last appointment, and were
explicitly given permission to return earlier to the clinic
in case of illness.
Discussion
Our study reports pre-treatment mortality and losses to
follow-up among ART-eligible children from a cohort
who were yet to initiate treatment at a West-African
clinic. The majority of deaths in our cohort occurred
in the first three months after eligibility and during
the period of preparation for ART. The pre-treatment
mortality rate observed in our setting is relatively higher
than reports from other sites; a study in rural Zambia
reported 10% mortality among ART-eligible children
with a mortality rate of 2.73 (95% CI: 1.7 – 4.18) per 100
child-years [14] while another study reported that 1%
of treatment-eligible children receiving care at an urban
ART program in Zambia died prior to ART initiation
[18]. In a large cohort of 1766 children in Cote d’Ivoire,
the reported loss-to-programme rate of 50.3/100 child-
years of follow up was also much lower than that
reported in this study though, it was not clear if the chil-
dren in that cohort were eligible for ART. One possible
reason for the relatively higher pre-treatment mortality
and loss-to-programme rates among ART-eligible chil-
dren in our setting is the advanced stage of clinical
disease and immunosuppression at diagnosis. Many chil-
dren in resource limited settings are only tested for HIV
as part of workup for recurrent or severe ill health;
we reported that 80% of the treatment-eligible children
attending our clinic were assessed as eligible for ART
either at or within 6 months of their being diagnosed
with HIV infection. The inclusion of home visits as part
of our patient follow-up protocol provides a more accur-
ate and complete ascertainment of survival status that
could have contributed to the higher mortality rates
observed in our cohort.
The proportion of children who initiated ART in our
clinic is comparable to that reported in a study in South
Africa where 39.5% (96/243) of ART-eligible children
started treatment [19] but considerably lower than fig-
ures reported from Cote d’Ivoire [15] and Zambia [14]
where 86% and 70% of ART-eligible children respectively
started therapy. The median time of 5.1 months from eli-
gibility to ART initiation in our cohort was comparable
Table 2 Association of baseline characteristics with outcomes among ART-eligible HIV-infected children enrolled in the
Paediatric HIV programme, MRC Unit, The Gambia, 2004–2010
Variable Started ART Died LTFU Transferred p-value
Total (n=223) 73 (32.7%) 30 (13.5%) 105 (47.1%) 15 (6.7%)
Sex: (n=223)
Female 35 (34.7%) 12 (11.8%) 48 (47.5%) 6 (5.9%) 0.868{
Male 38 (31.2%) 9 (7.4%) 57 (46.7%) 18 (14.7%)
Age at eligibility: (n=222)
Median in years (IQR) 4.7 (1.9 – 8.4) 5.1 (1.6 – 10.0) 1.9 (1.2 – 4.7) 7.4 (3.2 – 8.7) 0.0001ψ
< 2 years 19 (21.4%) 10 (11.2%) 57 (64.0%) 3 (3.4%)
2 – 4 years 21 (42.9%) 5 (10.2%) 22 (44.9%) 1 (2.0%)
≥ 5 years 33 (38.8%) 15 (17.7%) 26 (30.6%) 11 (12.9%) <0.001Ω
HIV type: (n=223)
HIV-1 68 (31.8%) 30 (14%) 103 (48.1%) 13 (6.1%) 0.065Ω
HIV-2 5 (55.6%) 0 2 (22.2%) 2 (22.2%)
WHO stage: (n=178)
1 or 2 34 (54%) 8 (12.7%) 16 (25.4%) 5 (7.9%)
3 or 4 33 (28.7%) 16 (13.9%) 59 (51.3%) 7 (6.1%) 0.003Ω
CD4% at eligibility: (n=196)
Median (IQR) 11% (8 – 14) 8% (4 – 11) 11% (8 – 15.0) 13% (8 – 14) 0.039ψ
<15% 55 (36.4%) 25 (16.6%) 60 (39.7%) 11 (7.3%) 0.574Ω
≥15% 18 (40.0%) 4 (8.9%) 21 (46.7%) 2 (4.4%)
Haemoglobin: (n=192)
Median (IQR) 9.6 (7.9 – 10.6) 9.5 (7 – 11.4) 9.1 (8.1 – 9.9) 10 (8.6 – 10.5) 0.262ψ
< 8 g/dl 20 (40%) 9 (18%) 20 (40%) 1 (2%) 0.245Ω
Vital status of parent: (n=173)
Single orphan 25 (35.7%) 6 (8.6%) 31 (44.3%) 8 (11.4%)
Double orphan 6 (37.5%) 3 (18.7%) 4 (25%) 3 (18.8%)
Both alive 37 (42.5%) 9 (10.4%) 39 (44.8%) 2 (2.3%) 0.073Ω
{ Chi-square test.
Ω Fishers exact test.
ψ Kruskall-Wallis test.
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after a median of 4.7 months [13], but more than twice
as long as the 2.1 months reported from rural Zambia
[14]. Another study from Zambia reported that children
eligible for ART at presentation in rural areas took longer
time to initiate treatment than children in urban areas
(3.6 vs. 0.9 months) [18].
Delays in treatment initiation among eligible children
are reported to be due to several factors [12-14,19,20]
some of which were observed in our cohort. Firstly, the
long process of pre-treatment counselling required repeated
clinic visits to ensure that care-givers are both willing
and capable of taking the responsibility of supporting the
child to take life-long medications with a high level of
adherence. Lack of caregiver readiness as assessed during
counselling sessions could prolong the process further.
This often proved difficult for patients from rural areas
and those with working parents though parents/caregivers
who were in HIV care, specifically those already ART andwith good adherence, underwent ‘accelerated’ counselling
with emphasis on the challenges of administering drugs
to children, drug-storage and side-effects. We however
did not collect information on the number of parents/
caregivers who completed the 4 pre-ART counselling
sessions among children who died or were LTFU.
A second factor for treatment delay was the time
required to obtain approval to start ART from the
national ART eligibility committee. The fortnightly occur-
rence of the meeting frequently resulted in eligible
children, whose caregivers had completed pre-ART coun-
selling, waiting for days (sometimes as long as one month
if the meeting date fell on a public holiday) to receive
approval to start treatment. The concept of the national
eligibility committee arose in the early days of ART avail-
ability in The Gambia when ART supplies were limited,
providers inexperienced and practical application of eligi-
bility criteria was still being debated. Though the com-
mittee now meets weekly, the inconvenience of travel






CD4% or absolute CD4 count
at eligibility Place of death
Disseminated Tuberculosis, Sepsis 13 years M 1 140 cells/mm3 Hospital
Disseminated Tuberculosis, Sepsis 8 years M 3 10 cells/mm3 Hospital
Kaposi Sarcoma 7 years M 4 - Hospital
Severe Malnutrition 8 months M 4 22% Hospital
Severe Malnutrition, Sepsis 19 months M 4 27% Hospital
Severe Malnutrition, Sepsis 8 years F 4 120 cells/mm3 Hospital
Tuberculosis 19 months F 3 13% Hospital
Tuberculosis 2 years M 3 9% Hospital
Tuberculosis 7 months M 3 10% Hospital
Tuberculosis 6 years M 3 30 cells/mm3 Hospital
Tuberculosis, Meningitis 11 years M 4 10 cells/mm3 Hospital
Very Severe Pneumonia 8 months M 3 8% Hospital
Unknown 2 years F 2 3% Home
Unknown 4 years F - 3% Home
Unknown 20 months M 4 9% Home
Unknown 1 month F 1 10% Home
Unknown 13 months F 3 19% Home
Unknown 23 months F - 7% Home
Unknown 2 years F 4 16% Home
Unknown 3 years M 2 13% Home
Unknown 19 months F - 8% Home
Unknown 13 years M - 20 cells/mm3 Home
Unknown 14 years M 2 320 cells/mm3 (8%) Home
Unknown 10 years F 1 20 cells/mm3 Home
Unknown 6 years M 1 160 cells/mm3 Home
Unknown 10 years M 1 10 cells/mm3 Home
Unknown 12 years M - 380 cells/mm3 (11%) Home
Unknown 12 years F 3 60 cells/mm3 Home
Unknown 6 years M 4 540 cells/mm3 Home
Unknown 9 years F - 90 cells/mm3 Home
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vices nationwide and the widespread availability of ART
favour decentralization of the committee to centres
involved in provision of ART and may help shorten the
time patients have to wait in order to initiate life-saving
treatment.
Thirdly, caregivers failed to attend follow-up appoint-
ments; almost 20% of treatment eligible children attended
only one clinic visit before being lost to follow-up. Poor
uptake of paediatric HIV services is multifactorial and rea-
sons include facility-related factors such as long queues,
overcrowding, negative staff attitudes; unemployment,
lack of money for food and transport, difficulty getting
time off work, absenteeism from school and fear of
social rejection from disclosure to family and neighbours
[21]. While the cost of transport was not a hindrance
to clinic attendance in our setting due to the practiceof reimbursement of transport costs for all patients, dis-
closure of HIV-status to a family member or friend was
a major factor for loss to follow-up among our adult co-
hort [12] and suggests that unwillingness to disclose the
child’s status to another caregiver may have contributed
significantly to failure to keep clinic appointments as well
as delays in initiation of ART among eligible children.
Disclosure of paediatric infection is multifaceted being
dependent on caregiver and family characteristics such as
biologic relationship, caregiver permanence, caregiver
beliefs and psychosocial function, as well as child-specific
factors such as age, developmental stage, cognitive abil-
ities and psychosocial function [22]. A child’s positive sta-
tus usually indicates maternal infection and the resultant
anxiety, fear of blame, social and healthcare discrimin-
ation as well as marital abandonment may negatively in-
fluence the mother’s acceptance of the HIV status of the
Table 4 Risk factors associated with death and loss to programme before initiation of ART among HIV-infected
children eligible for ART in the Paediatric HIV programme, MRC Unit, The Gambia, 2004–2010










Female 99 (45.2%) 1.0 1.0 1.0 1.0
Male 120 (54.8%) 1.16 (0.56 – 2.41) 0.686 1.23 (0.43 – 3.51) 0.700 0.94 (0.67 – 1.32) 0.731 1.15 (0.68 – 1.95) 0.600
Age category: (n=219)
< 2 years 88 (40.2%) 0.86 (0.38 – 1.94) 0.712 1.64 (0.50 – 5.38) 0.415 2.41 (1.61 – 3.61) <0.0001 2.06 (1.12 – 3.83) 0.023
2 – 4 years 49 (22.4%) 0.66 (0.24 – 1.83) 0.429 0.50 (0.09 – 2.64) 0.410 1.58 (0.97 – 2.58) 0.069 0.95 (0.43 – 2.10) 0.896
≥ 5 years 82 (37.4%) 1.0 1.0 1.0 1.0
WHO clinical stage: (n=174)
1 or 2 60 (34.5%) 1.0 1.0 1.0 1.0
3 or 4 114 (65.5%) 1.49 (0.63 – 3.55) 0.367 2.98 (0.78 – 11.31) 0.109 2.43 (1.51 – 3.90) <0.0001 1.92 (1.05 – 3.53) 0.035
CD4%: (n=193)
<15% 148 (76.7%) 1.69 (0.59 – 4.86) 0.330 1.26 (0.39 – 4.09) 0.700 0.90 (0.58 – 1.42) 0.662 1.23 (0.67 – 2.26) 0.499
≥15% 45 (23.3%) 1.0 1.0 1.0 1.0
Vital status of parent: (n=169)
Single orphan 68 (40.2%) 0.75 (026 – 2.11) 0.582 0.71 (0.23 – 2.20) 0.548 0.89 (0.58 – 1.38) 0.612 0.90 (0.52 – 1.57) 0.720
Double orphan 16 (9.5%) 1.93 (0.52 – 7.17) 0.323 1.32 (0.30 – 5.82) 0.711 0.95 (0.43 – 2.10) 0.903 1.12 (0.46 – 2.70) 0.800
Both alive 85 (50.3%) 1.0 1.0 1.0 1.0
Eligibility period: (n= 219)
Jun 2004 – Dec
2005 42 (19.2%) 1.0 1.0 1.0 1.0
Jan 2006 – Jan
2010 177 (80.8%) 1.19 (0.50 – 2.83) 0.690 3.59 (0.40 – 32.4) 0.254 1.86 (1.18 – 2.93) 0.007 2.06 (0.86 – 4.96) 0.106
a Children were lost to the programme if they died or were lost to follow-up.
b 4 children excluded from the analysis: 1child had an of incorrect date of HIV eligibility while 3 children had incorrect date of exit.
Proportional hazards assumption was met for all Cox proportional hazard models as assessed by the global test based on the Schoenfeld residuals.
Ф Adjusted for Sex, Age, WHO stage, CD4% and eligibility period.
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der health-care seeking and social support, and may lead
to difficulties in reacting to the options and advice given
by health workers [23-25]. Maternal depression (in cases
of vertical transmission) and concurrent HIV or other
comorbidities may also affect the mother’s ability to care
for the child; the belief that the child might die any mo-
ment may cause her not to take proper care of the child
anymore. In circumstances where the biologic parents
may have died or may be too ill to care for the child,
responsibility for care is shifted to one or more relatives
or family friends; poor coordination amongst multiple
caregivers may also compromise the quality of care espe-
cially where secondary caregivers have not been disclosed
to and therefore do not understand the importance of
regular clinic visits or adherence to prescribed medica-
tions [21]. Studies from sub-Saharan Africa suggest that
whilst many caregivers appreciate shared childcare, sus-
tained adherence and community support as benefits
of disclosing a child’s HIV status to others, many stillbelieve that disclosure to others could have negative effects
[21,23,26]. Community-based support groups have been
shown to play a major role in providing continuous
support to caregivers of HIV-infected children [27] and
though several support groups were linked to our clinic,
we did not routinely collect data of patient/caregiver
membership with such groups or assess what impact this
had on their quality of life. Disclosing a diagnosis of HIV
infection to a child has been suggested to have direct
benefits for adherence to ART and among adolescents is
associated with higher retention in care [26,28,29]. The
average age of disclosure reported among children in
sub-Saharan Africa is 8 years [30,31]; 75% of those LTFU
in our cohort (data not shown) were less than 5 years of
age at eligibility and therefore too young for a disclosure
their HIV status.
Lastly, we report that tuberculosis was the most com-
mon cause of death among treatment-eligible children
and may have also been an underlying cause of death
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Figure 2 Cumulative incidence of loss to programme following eligibility for cART among HIV-infected children enrolled in the
Paediatric HIV programme, MRC Unit, The Gambia, 2004 – 2010. Plot A shows the cumulative incidence of loss to programme before
starting treatment for all ART-eligible patients; Plots B, C, and D show significant unadjusted associations between age category, WHO clinical
stage and eligibility period respectively, and the risk of becoming lost to the programme.
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limited settings in which tuberculosis has been cited as a
major reason for delayed treatment initiation [19,20] as
well as the most common co-morbidity associated with
early deaths among both ART naïve and experienced
children [13,14,32]. As such, treatment for concurrent
tuberculosis could also have contributed to the delay
in initiation of ART.
Overall, 60% of ART-eligible children in our pro-
gramme died or were lost to follow-up without starting
treatment giving a loss-to-care incidence rate of 128 per
100 child-years of follow-up. We observed that the chil-
dren who were lost to care were significantly more likely
to be less than 2 years of age at ART eligibility or to have
advanced clinical disease (predominantly tuberculosis
and severe malnutrition - data not shown). Children aged
less than 2 years or in WHO stage 3 or 4 had almosttwice the risk of being lost to the programme before
starting treatment respectively compared with those 5 years
of age or older and those in WHO stage 1 or 2. The ob-
servation that just over half of children LTFU were in
WHO stage 3 or 4 coupled with the relatively shorter
median time to LTFU from eligibility compared with the
time to initiation of ART (4.2 vs 5.1 months), suggests
that many of those LTFU may have died as a result of
rapid disease progression and advanced HIV disease dur-
ing the time of preparation for ART and may have not
even completed the process. This observation supports
the 2010 WHO recommendation that ART be initiated
for all HIV-infected infants and children between 12 and
24 months of age irrespective of their immunological
threshold or clinical stage [5]. In our study the vital status
of the parent was not related to death or loss to care, which
was surprising as HIV-infected orphans in sub-Saharan
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treatment as well as reduced clinic attendance [33,34] .
Children assessed as eligible for ART between January
2006 and January 2010 using the revised 2006 guidelines
were observed to have had a significantly higher risk of
being lost to programme compared with those assessed
as eligible between June 2004 and December 2005 based
on the 2003 WHO treatment guidelines. As the paediat-
ric cohort was a sub-cohort of a much larger adult
cohort, this may be attributable to the increase in clinic
enrolment over time and the reduced ability of clinic staff
to effectively manage the patient load. This risk remained
albeit insignificantly after adjusting for the effect of age,
clinical stage and other variables.
As the only centre in the country performing viro-
logical tests for the diagnosis of HIV infection in children
<18 months of age and the major paediatric HIV referral
clinic in The Gambia, we experienced a good uptake of
paediatric HIV services at our HIV clinic, which however,
is not representative of paediatric HIV care in West
Africa as patients had the advantage of reimbursement of
all transport costs incurred in clinic visits, free treatment,
nutritional support and provision and school fees for
all children enrolled in school up till the age of 18 years.
This coupled with the small size of our paediatric cohort,
limit the generalizability of findings. There were however
several limitations to this study; data were incomplete for
many key variables such as WHO stage or CD4 T-cell
percentage at eligibility and these children were classi-
fied based on immunologic or clinical criteria alone. Sec-
ondly, children with moderate or severe malnutrition in
our setting were initially classified as WHO stage 3 or 4
respectively without assessing their response to nutritional
support and treatment and thus may have been misclassi-
fied as eligible for treatment. Unreported deaths among
ART-eligible children LTFU in our cohort suggest that
the reported mortality rate may be underestimated; in
addition, a good proportion of the children ineligible for
ART and also LTFU may have progressed to an advanced
stage of HIV-disease and died as they became eligible.Conclusion
The results of our study have shown that HIV-infected
children in The Gambia are enrolled into care at an
advanced stage of disease with severe immunosuppres-
sion and a significant number of these treatment-eligible
children die before initiating therapy. Only one-third of
ART-eligible children go on to initiate ART but face a
number of out-of-program and in-program delays before
treatment is eventually commenced. Developing strat-
egies to ensure early identification of HIV-infected chil-
dren before they become eligible for ART, elimination
of obstacles to prompt initiation of therapy as well asinstituting measures to reduce losses to follow-up, will
improve the overall outcomes of HIV-infected children.
Methods
Study setting and participants
This study was conducted in MRC HIV research clinic
located in the urban area of Greater Banjul, the Gambia.
The clinic established an adult cohort in 1986 with
approval from the Joint Gambian Government/MRC
Ethics Committee and started enrolment of children in
1993 based on written informed consent by the parent
or legal guardian, with the adoption of a family-centred
model of HIV-care. Paediatric patients consist of exposed
or infected infants and children of adults enrolled in the
MRC cohort, children with a positive HIV serologic test
referred to the clinic from the MRC Clinical services or
other health-care services in the country. HIV-exposed
infants referred from other PMTCT programmes were
also enrolled in the paediatric clinic. Provision of ART in
The Gambia began in October 2004 through the support
of the Global Fund. Nutritional support is provided and
school fees for all children enrolled in school up till
the age of 18 years are paid. All treatments, including
cART, and treatment monitoring are provided free of
charge and the parents/guardians of enrolled children
also receive reimbursement of transport costs incurred in
clinic visits.
Acquisition of clinical data in an electronic system
includes capture of demographic characteristics, social
history, basic anthropometric measurements, complete
blood count, serum biochemistry, CD4 T-cell profile,
chest radiograph, opportunistic/concomitant infections
and clinical stage. Patients are required to be seen in
clinic at least once every 3 months for follow-up clinical
assessment, and CD4 T-cell monitoring is performed
every 6 months or earlier if clinically indicated. All chil-
dren receive daily cotrimoxazole prophylaxis [35,36].
Selection for ART
Eligibility for ART was determined using immunological
and/or clinical criteria based on the Gambian National
ART guideline [37] and WHO paediatric ART guidelines
that were in place at the time of enrolment; for children
enrolled on or before December 31 2005, eligibility was
based on the 3-stage 2003 guidelines while for those
enrolled from January 2006 eligibility was based on the
4-stage 2006 revision of the guidelines [38,39]. Following
a further revision of the treatment guidelines in June
2008 [WHO 2008], ART was recommended for all chil-
dren <12 months of age with confirmed HIV infection.
In addition, all children were required to have at least
one identifiable caregiver who would serve as a ‘treat-
ment supporter’ and take responsibility for the adminis-
tration of the child’s medications. Pre-ART counselling
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a minimum of four one-on-one counselling sessions over a
period of three to six weeks before selection was processed
and confirmed by the national eligibility committee.
Patients who did not come to the clinic for at least
90 days beyond their last scheduled visit were considered
LTFU and visited at home by trained field workers to
ascertain survival status or change of address. For chil-
dren who died at home, deaths were verified by close
family members and cause of death ascertained by verbal
autopsy. Recruitment of children into the programme
ended in January 2010 as part of the transition process
to transfer patient care from the MRC to the Gambian
national health care system.
Laboratory methods
HIV diagnosis and CD4 measurement
Screening for HIV-1 and HIV-2 infection was done using
a protocol described in detail elsewhere [40]. In children
<18 months of age, HIV infection was diagnosed by two
polymerase chain reaction (PCR) tests. Percentages and
absolute counts of CD4 T lymphocytes were determined
on a FACS Calibur (Becton Dickinson, US) using BD
MultiTest reagents and MultiSet software (BD Immuno-
cytometry Systems).
Statistical analysis
For the purpose of this analysis, eligibility for ART
was determined from June 2004 when sensitization of
patients began in preparation for the roll-out of ART, to
January 2010 when patient recruitment ended. Children
already in the paediatric cohort and eligible for treatment
but who died or were lost to follow-up before June 2004
were excluded from the analyses. Severe anaemia was
defined as haemoglobin <8 g/dl [41]. Distributions of
categorical variables were compared between the four pos-
sible outcomes: [a] initiation of ART; [b] death; [c] loss to
follow-up or [d] transfer by chi square statistics or Fisher
exact test as appropriate. Continuous variables were com-
pared using Kruskall-Wallis non-parametric test.
Follow-up duration in person-time was calculated from
the date the children were assessed as eligible for ART;
children who started ART were right-censored on the
date treatment started; those who requested transfer
were followed through to the date of transfer. Patients
who died were followed to their date of death if known
or date last seen alive. To avoid immortal person-time
bias, patients LTFU were right-censored 90 days after
the date of their last clinic visit (as loss to follow-up was
not possible before this time). The probability of loss to
programme following ART-eligibility was described
using cumulative incidence curves and summarised by
mortality rate and loss to programme rate (incident rate
for the composite endpoint of death and LTFU) reportedper 100 child-years of follow-up respectively. Cox pro-
portional hazards regression models were used to iden-
tify baseline characteristics associated with death or a
loss to programme. The proportional hazards assump-
tion was assessed for all models by the global test based
on the Schoenfeld residuals. All statistical analyses were
performed with STATA release 11.1 software (Stata
Corp., College Station, TX, USA) and statistical signifi-
cance defined as p < 0.05 (two-sided).
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